MEI Pharma is a late-stage pharmaceutical company focused on development and oncology capabilities to identify and develop therapies for the treatment of cancer. The company has four clinical-stage development programs with approaches to inhibiting cancer, including epigenetics, cell signalling and cancer metabolism: ME-401, an oral phosphatidylinositol 3-kinase delta inhibitor; Voruciclib, an oral cyclin-dependent kinase inhibitor; ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex; and Pracinostat, an oral histone deacetylase inhibitor being evaluated in a pivotal Phase 3 global registration clinical trial for the treatment of adults with acute myeloid leukemia.
Research suggests that directors know their companies better than the market. For many investors it is intuitive that following the trading patterns of directors and other company insiders can lead to successful investing. They often have detailed knowledge about their companies and generally know when the shares are incorrectly valued. However, that is not always true and with large numbers of trades reported every day on exchanges around the world, it is difficult to know which to follow.
SmartInsider provides valuable insight by supplementing and analysing reported transactions to achieve real insight with a focus on identifying the ‘Smart Insiders’ and highlighting the stand-out transactions they make. Our proven track-record and thirty year pedigree are backed by more recent statistical analysis of historical data.
Our service offers director dealing reports, company reports and monthly summaries with a fully interactive website for further research. We can also provide quant feeds and customised alerts to suit every need at the frequency preferred. SmartInsider covers all markets with a regulatory requirement to report insider activity, over 60,000 companies across 55 markets.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.